A truncated fragment of Ov-ASP-1 consisting of the core pathogenesis-related-1 (PR-1) domain maintains adjuvanticity as the full-length protein. Issue 16 (15th April 2015)

• Record Type: Journal Article
• Authors: Guo, Jingjing; Yang, Yi; Xiao, Wenjun; Sun, Weilai; Yu, Hong; Du, Lanying; Lustigman, Sara; Jiang, Shibo; Kou, Zhihua; Zhou, Yusen
• Is Part Of: Vaccine. Volume 33:Issue 16(2015)
• Page Start: 1974
• Page End: 1980
• Publication Date: 2015-04-15
• Subjects: Ov-ASP-1 Onchocerca volvulus activation-associated secreted protein-1 -- ASPPR PR-1 domain of Ov-ASP-1 -- CAP CRISPS, Ag 5 and PR-1 -- CRISPS cysteine-rich secretory protein -- Ag 5 antigen 5 -- PR-1 pathogenesis-related 1 -- OVA ovalbumin -- HBsAg Hepatitis B virus surface antigen -- FBS fetal bovine serum; Adjuvant -- Ov-ASP-1 -- Pathogenesis-related-1 family -- Th1/Th2 immune responses; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2015.02.053
• Languages: English
• ISSNs: 0264-410X

Abstract

Highlights: Ov -ASP-1, an onchocerca volvulus protein, has good adjuvanticity for protein antigens. A truncated Ov -ASP-1 (ASPPR) maintains adjuvanticity as the full-length of Ov -ASP-1. ASPPR augments humoral and cellular immune responses elicited by protein antigens. ASPPR has potential to be further developed as a novel adjuvant for human use. Abstract: The Onchocerca volvulus activation-associated secreted protein-1 ( Ov -ASP-1) has good adjuvanticity for a variety of antigens and vaccines, probably due to its ability activate antigen-processing cells (APCs). However, the functional domain of Ov -ASP-1 as an adjuvant is not clearly defined. Based on the structural prediction of this protein family, we constructed a 16-kDa recombinant protein of Ov -ASP-1 that contains only the core pathogenesis-related-1 (PR-1) domain (residues 10–153), designated ASPPR. We found that ASPPR exhibits adjuvanticity similar to that of the full-length Ov -ASP-1 (residues 10–220) for various antigens, including ovalbumin (OVA), HBsAg protein antigen, and the HIV peptide 5 (Pep5) antigen, but it is more suitable for vaccine design in ASPPR-antigen fusion proteins, and more stable in PBS than Ov -ASP-1 stored at −70 °C. These results suggest that ASPPR might be the functional region of Ov -ASP-1 as an adjuvant, and therefore could be developed as an adjuvant for human use.